BRAF and neoplasm: In the current subgroup analysis of the international, multicenter, single-arm phase 2 FIREFLY-1 trial, we demonstrated that tovorafenib monotherapy achieved clinically meaningful, rapid, and durable (while on treatment) tumor responses in children and young adults with BRAF-altered sporadic relapsed/refractory OPG.